Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Strategy

AbbVie's plan B

What AbbVie really needs from Shire besides inversion benefits

July 21, 2014 7:00 AM UTC

Clinical setbacks and a rapidly evolving HCV landscape have left AbbVie Inc. less insulated from potential biosimilar competition for blockbuster Humira adalimumab. Now that Shire plc has decided to accept AbbVie's takeout bid, the specialty pharma's rare disease portfolio and pipeline, along with its ADHD franchise, could help fill a potential revenue gap.

AbbVie's fifth offer since May, when the pharma started to privately court the Irish company, values Shire at £31.4 billion ($54.5 billion) and is a 35% premium to the biotech's first bid of £23.6 billion ($39.9 billion). The deal is 46% cash and 54% stock...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article